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6 Oral Presentationschimerism or failure to achieve neutrophil recovery by day 42. Me-
dian patient age and weight was 22 years (r: 0–69) and 61 kg (r: 4–
149 kg), respectively, with 66 having had a prior autologous trans-
plant. Time from diagnosis to transplant was 13.3 months (1.26–
250 months), 57 patients were CMV1, 186 received a sex-matched
graft, 132 ABO-matched, 168 minor ABO-MM, and 229 major
ABO-MM. Median graft cell doses were 3.8  107 nucleated cells
(NC)/kg (r: 0.7–48.9) and 4.6  105 CD34/kg (r:0.4–275.3).
Fifty-seven received 6/6 HLA-matched units, 196 received at least
one 5/6 matched unit and 286 received at least one 4/6 matched
unit. GF was observed in 43/338 (12.7%) after MA and 36/201
(17.9%) after RI UCBT. Risk factors associated with GF in logistic
regression were transplantation of HLA mismatched units (5/6
match, OR 9.13, 95%CI, 1.19–70.38; 4/6 match, OR 11.66,
95%CI 1.53–89.00; p\ .01), treatment of non-malignant disease
(OR 2.55, 95%CI, 1.35–4.81, p\ .01), low CD34 cell dose (top
low quartile OR 2.33, 95%CI, 1.07–5.05; bottom low quartile,
OR 3.11, 95%CI, 1.44–6.70; p \ .01), and use of a RIC (OR
2.40, 95%CI 1.35–4.26; p\ .01). Patients who received a prior au-
tologous transplant had lower odds of GF (OR 0.12, 95%CI, 0.03–
0.52, p\ .01). Factors not impacting risk of GF were recipient age,
sex-match, ABO-match, CMV serostatus, performance status, diag-
nosis, disease risk, interval from diagnosis to transplant, NC dose,
and CD3 cell dose. In addition to CD34 cell dose and HLA match,
patients with non malignant disease and recipients of a RIC are at
higher risk of GF. These results support the need for greater invest-
ment in banking UCB with larger cell doses and HLA diversity and
development of improved strategies for overcoming GF in high risk
patient populations.10
COSTIMULATORY BLOCKADE (CSB) DURING MIXED LYMPHOCYTE RE-
ACTION (MLR) PREVENTS IL27 UPREGULATION AND SIGNALLING
Gorgun, G.1, Philpot, P.A.1, Naxerova, K.2, Kohane, I.S.2,
Nadler, L.M.1, Guinan, E.C.1,2. 1Dana-Farber Cancer Institute; 2Chil-
dren’s Hospital, Boston, MA.
Numerous methods for selectively depleting or manipulating al-
loantigen (alloAg) specific CD4 T cells (CD4 T) are being studied
for their potential in improving transplant outcomes by limiting
GVHD or graft rejection. However, their effects on off-target
CD4 T cellular pathways and functions and on other PBMC are
not well described. We used global gene expression profiling
(GEP) to elucidate the molecular impacts on bystander PBMC after
inducing alloAg specific CD4 T anergy by CD28:B7 costimulatory
signal blockade (CSB) via humanized anti B7.1/B7.2 MoAbs. Mim-
icking our ex vivo clinical anergization protocol, PBMC were iso-
lated from fully-HLA mismatched healthy donors (n 5 12) to
perform ex vivo primary MLR1/-anti B7.1/B7.2 MoAbs. CSB in-
hibited mean proliferation by 73% after 72 h of MLR. GEP was
performed using Affymetrix hu133 plus2 chips on monocytes
(Mo), CD4 and CD8 T, B and NK cells purified from these
MLR. Despite low published frequencies (1–10%) of alloAg-spe-
cific CD4 T, we detected global gene expression variance (P \
0.05) between CD4 T isolated from MLR1/-CSB suggesting ef-
fects on non-alloAg specific CD4 T. Analysing these differentially
expressed genes by cellular pathway highlighted those active in
cell proliferation and differentiation. Particularly, differences in
IL27 signaling molecules in Mo and CD4 T were prominent.
IL27, a heterodimer of p28 and EBV-Induced gene 3 (EBI3) and
IL12 family member produced by APC, signals through its recep-
tor, IL27R, on CD4 T. IL27 regulates adaptive immunity by con-
trolling T cell proliferation, Th1 differentiation and IFNg
synthesis. Both p28 and EBI3 gene and protein expression levels
were decreased in Mo from MLR1CSB. After CSB, CD4 T showed
decreased IL27R and STAT3 expression and inactivation of
pSTAT1 and NFkB. Intracytoplasmic cytokine (ICC) analysis
showed decreased IL2 and IFNg expression in CD4 T, decreased
IL15 and increased IL10 in Mo from MLR1CSB supporting the
negative effect of IL27 on Th1 differentiation. These data suggest
that CD28:B7 signaling during MLR is required for Mo production
of IL27. Decreased expression of IL27R, pSTAT1 and NFkB after
CSB may contribute to CD4 T alloAg anergy induction by sup-pressing effector cytokines and Th1 differentiation. CD28:B7 mod-
ulation of IL27 and IL27R emphasizes that targeted therapies used
in the complex environment of human PBMC may have effects un-
predicted by in vitro clonal systems, which may be important in the
functional outcome of the intervention.11
RISK FACTOR ANALYSIS FOR THE DEVELOPMENT OF RESTRICTIVE AND
OBSTRUCTIVE PULMONARY FUNCTION CHANGES AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
Rabanus, R., Hahn, J., Andreesen, R., Holler, E., Hildebrandt, G.C.
University of Regensburg Medical Center, Regensburg, Germany.
Pulmonary complications after allogeneic stem cell transplanta-
tion (allo-SCT) significantly contribute to morbidity and mortality.
We analyzed 207 patients receiving allo-SCT at our institution be-
tween 1998 and 2005 for the development of restrictive (PRC) and
obstructive (POC) pulmonary function changes. Pulmonary func-
tion tests (PFT) were performed before and routinely every 3 to 6
months after allo-SCT. After follow-up .2 years, PFTs were ob-
tained yearly. 142 patients were included according to the availabil-
ity of PFTs; 65 patients were excluded due to early mortality and/or
the lack of PFT data. PRC were defined as a forced vital capacity
(FVC) at least once#90% of pre-transplant values, POC as a forced
expiratory volume (FEV1) at least once #80% of baseline. Median
time of follow-up was 1071 days (107–2924). For PRC, median time
of first onset was at 180 days (30–1482) and for POC at 270 days
(60–1800) after allo-SCT. The cumulative incidence for PRC was
70.7% and for POC 34.2%. Risk factor analysis included patient/
donor age and gender, type of transplant, stem cell source, condi-
tioning regimen intensity, TBI, T cell depletion, pretransplant-
CMV serology of donor and recipient, acute (aGVHD) and chronic
GVHD (cGVHD) and previous thoracic irradiation.
In univariate analysis, positive patient CMV serology was associ-
ated with the development of both PRC (p 5 0.05) and POC (p 5
0.005), whereas CMV immunity of the donor affected only the risk
of POC (p5 0.002). In addition, the cumulative incidence of POC
rose to 57.3% when both donor and recipient had positive pretrans-
plant anti-CMV immunity (p 5 0.0002) and to 51.4% in patients
with proven CMV reactivation (p 5 0.1). cGVHD increased the
risk of POC (p 5 0.0045) but not of PRC (p 5 0.127). Risk factors
for PRC but not POC were bone marrow derived stem cells (p 5
0.045) and female patient gender (p 5 0.057). In multivariate anal-
ysis, cGVHD (p5 0.037; HR 2.3 [1.1–5.0]), anti-CMV IgG positiv-
ity of the donor only (p 5 0.026; HR 2.3 [1.1–5.29]) and of both
donor and recipient combined (p5 0.004; HR 3.7 [1.5–9.3] were in-
dependent risk factors for POC, the latter also being the only inde-
pendent risk factor identified for PRC. Therefore, our data confirm
the previously described association between cGVHD and the de-
velopment of pulmonary obstructive changes. In addition, this anal-
ysis strengthens the concept, that anti-CMV immunity and CMV
reactivation contribute to pulmonary function impairment after
allo-SCT.12
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR TRANSFU-
SION-DEPENDENT THALASSEMIA – A CIBMTR AUDITED RETROSPEC-
TIVE ANALYSIS OF 51 CONSECUTIVE PATIENTS
Jaing, T.-H.1, Tan, P.2, Rosenthal, J.3, Chan, L.L.4, Lin, H.-P.5,
Tan, P.-L.6, Nademanee, A.3, Karanes, C.3, Gjertson, D.7, Wang, B.8,
Petz, L.8, Chow, R.8. 1Chang Gung Children’s Hospital & University,
Linko, Taiwan; 2Mount Elizabeth Hospital, Singapore; 3City of Hope
National Medical Center, Duarte, CA; 4University of Malaya Medical
Center, Kuala Lumpur, Malaysia; 5Subang Jaya Medical Center, Ma-
laysia; 6National University Hospital, Singapore; 7UCLA School of Pub-
lic Health, Los Angeles, CA; 8StemCyte International Cord Blood Center,
Arcadia, CA.
UCBT offers a cure for thalassemia and has advantages as a stem
cell source for minorities where thalassemia is prevalent, but cell
Oral Presentations 7dose is critical for UCBT. Previously mortality risks outweigh ben-
efits in using UCBT for thalassemia. With strategies that maximize
cell dose – using non-red cell reduced but plasma depleted (PD) CB,
no post-thaw wash (NW), and double cord transplantation (DCT) –
promising results may be achieved with UCBT in young thalasse-
mics. Between 7/2001 and 1/2006, 63 CB products were infused af-
ter Bu/Cy/ATG myeloablation in 51 pediatric thalassemia major
patients (11 DCT & 1 re-transplant) at 14 transplant centers
(TC) using 82% PD CB with 92% NW. Patient status: 20 Pesaro
class 1, 11 class 2, 1 class 3, and 19 status unknown. Median age
was 4.3 years (range 0.3–20 years) with a median weight of 17 kg
(range 4–45 kg). The data was audited by TC, NMDP and on-
site by CIBMTR with 97.3% accuracy. No significant adverse
events were observed despite major ABO incompatibility in some
cases and NW. Cumulative incidence estimates of neutrophil
(ANC500), platelet 20K and platelet 50K (plt 20 & 50K) engraft-
ment with donor chimerism were 86 6 8%, 74 6 9% and 74 6
9%, and median times to ANC500, plt 20K and 50K engraftment
were 17 days (range 11–32), 40 days (range 16–135) and 60 days
(range 30–144) after transplantation respectively. 7 patients died in-
cluding 2 deaths prior to day 20 and one due to traumatic head in-
jury. 42 patients engrafted, 9 with autologous recovery, and 38
patients are alive with a mean and median follow up time of 537
and 296 days respectively (range 8–2,691 days) as of May 2007. Re-
sults appear to show improvement with TC experience TC (.5
cases of UCBT for thalassemia) and NW. Patients receiving PD
versus red cell depletion (RCD) CB were compared by matched-
pair analyses where patients were matched by TC experience,
wash status, age, weight, TNC dose, and #HLA matches (Paired
Prentice-Wilcoxon Test). The results (table) showed fewer autolo-
gous recovery (p5 0.04) and better thalassemia-free survival (DFS;
p5 0.01) for PD compared to RCD patients. Overall survival (OS)
and transplant-related mortality (TRM) also trended in favor of PD
patients (both p5 0.08). To our knowledge, this is the largest multi-
institutional UCBT series for thalassemia and demonstrate that at
experienced TC, 93 6 6% ANC engraftment and 88 6 8% 1-
year DFS are attainable, when cell dose is optimized with PD
CBU, no post-thaw wash and DBT when necessary.
Autologous
ANC500 Plt 50 K Recovery TRM OS DFSP-value NS NS 0.04 0.08 0.08 0.01
In favor of PD PD PD PDNS 5 Not Significant.
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THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION
(AlloSCT) FOR THE TREATMENT OF THERAPY-RELATED MYELODYS-
PLASTIC SYNDROME (tMDS) AND ACUTE MYELOID LEUKEMIA (tAML)
VARIES CONSIDERABLY BY RISK FACTOR: AN OBSERVATIONAL STUDY
FROM THE CENTER FOR INTERNATIONAL BLOOD AND MARROW
TRANSPLANT RESEARCH (CIBMTR)
Litzow, M.R.1, Perez, W.S.2, Tarima, S.2, Keating, A.3, Sierra, J.4,
Tallman, M.S.5, Weisdorf, D.J.6. 1Mayo Clinic Rochester; 2Center for
International Blood and Marrow Transplant Research; 3Princess Mar-
garet Hospital for Children; 4Hospital de la Santa Creu i Sant Pau;
5Northwestern Memorial Hospital; 6University of Minnesota Medical
Center.
We report outcomes of alloSCT for tMDS and tAML in 868 sub-
jects transplanted between 1990 and 2004 at 211 centers in 33 coun-
tries. 21% were#19 years old (yo); 55% were female and 63% had
tAML (including 30% with prior tMDS). Prior treatment was che-
motherapy in 43%, chemotherapy and radiation therapy in 51%
and radiation therapy alone in 4%. Prior diagnoses included Hodg-
kin lymphoma (23%) and non-Hodgkin lymphoma (21%), breast
cancer (16%), ALL (12%), sarcoma (8%), germ cell tumor (6%),
and autoimmune disorders (5%). Cytogenetic data (cd) at the
time of transplant were known in 84%: good prognosis 4%, inter-
mediate 61% and poor 34%. The IPSS score at diagnosis for sub-jects with tMDS was intermediate-2 or high in 54%. At
transplant, 51% of subjects with tAML were in first complete remis-
sion (CR1), 7% $ CR2, 15% in relapse and 27% were primary in-
duction failures. For the tMDS pts, 37% had been treated with
other modalities before receiving an alloSCT. Pre-transplant con-
ditioning regimen was myeloablative (M) 77% and reduced inten-
sity (RI or non-M) in the remainder. Donors were related 38%
and unrelated 62%; 66% of the grafts were bone marrow and
34% peripheral blood stem cells. Cumulative incidence of acute
GVHD (grade II-IV) @100 days was 39% (95% confidence interval
[CI]), 35–42). Outcomes, with a median follow-up of 61 (range, 3–
187) months were: In multivariate analysis (MVA), DFS and OS
were lower in subjects .35 yo, with poor prognosis cd, AML not
in CR or untreated MDS, or with a mismatched related or unrelated
donor. The use of a RI or non-M conditioning regimen did not im-
prove outcomes in the MVA. Survival was significantly better in pts
\35 yo, with good or intermediate risk cd, disease control at the
time of transplant and having a matched related or complete or par-
tially matched-unrelated donor. The 5 year survival was 50% (95%
CI, 39–61) with all 4 good risk factors (grf); 25% (95% CI, 20–31)
with any 3 grf, 19% (95% CI, 14–24) with any 2 grf, 12% (95% CI,
8–18) with only 1 grf, and only 4% (95% CI, 0–15) without any of
these factors. In conclusion, easily identifiable risk factors predict
outcome after alloSCT for tMDS and tAML.
5 year probability
Outcome: (95% CI)Chronic GVHD 30 (27–33)
Treatment-related mortality (TRM) 48 (44–51)
Relapse 31 (28–34)
Disease-free survival (DFS) 21 (18–24)
Overall survival (OS) 22 (19–26)14
UNRELATED CORD BLOOD TRANSPLANTATION AFTERMYELOABLATIVE
CONDITIONING IN 98 ADULT PATIENTSWITH ACUTE LEUKEMIA: A SIN-
GLE-INSTITUTE EXPERIENCE IN JAPAN
Ooi, J., Takahashi, S., Tomonari, A., Tsukada, N., Konuma, T.,
Kato, S., Kasahara, S., Tojo, A., Asano, S. Institute of Medical Science,
University of Tokyo, Tokyo, Japan.
We analyzed outcomes and risk factors after unrelated cord blood
transplantation (CBT) for 98 adult patients with acute leukemia.
Between August 1998 and June 2007, 98 adult patients with acute
leukemia were treated with unrelated CBT at The Institute of Med-
ical Science, University of Tokyo. Diagnoses at transplantation in-
cluded de novo AML (n 5 55), ALL (n 5 25), and MDS-related
secondary AML (n 5 18). 59 (60%) patients were transplanted in
an advanced status of the disease (defined as acute leukemia in third
or subsequent complete remission, not in remission, or with high-
risk cytogenetics). All patients received four fractionated 12 Gy total
body irradiation and chemotherapy as myeloablative conditioning.
95 patients received standard cyclosporine (CyA) and methotrexate,
and 3 patients received CyA only as a graft-versus-host disease
(GVHD) prophylaxis. Among the patients the median age was 40
years (range, 18–55 years), the median weight was 56 kg (range,
36–76 kg), the median number of cryopreserved nucleated cells
was 2.46  10 7/kg (range, 1.16–5.29  10 7/kg) and the median
number of cryopreserved CD34 positive cells was 0.93  10 5/kg
(range, 0.15–8.97 10 5/kg). 92 patients had myeloid reconstitution
and the median time to more than 0.5 10 9/L absolute neutrophil
count was 21 days. A higher CD34 positive cell count was indepen-
dently associated with faster neutrophil recovery (p 5 0.0001). A
self-sustained platelet count more than 50  10 9/L was achieved
in 86 patients at a median time of 42 days. Acute GVHD greater
than or equal to grade III occurred in 6 of 92 evaluable patients
and chronic GVHD occurred in 67 of 84 evaluable patients. Among
67 chronic GVHD patients, 19 patients were extensive type. 69 pa-
tients are alive and free of disease at between 116 and 3322 days after
CBT. With a median follow-up of 1677 days, the probability of dis-
ease-free survival (DFS) at 5 years was 68.5 6 5%. The 5-year
